Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANATEE: RO7204239 + Risdiplam in Spinal Muscular Atrophy
NCT05115110Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing RO7204239 + Risdiplam with Placebo + Risdiplam (2 arms). Primary endpoints: Percentage of participants with adverse events up to 4.5 years, Incidence of relevant echocardiographic parameter z scores > 2 up to 4.5 years and 16 more. Started Jun 2022; status: completed.
02
Drugs
emugrobart
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05115110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115110.